Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Trial Profile

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Trenonacog alfa (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Aptevo Therapeutics; Emergent BioSolutions; Inspiration Biopharmaceuticals
  • Most Recent Events

    • 13 Dec 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Feb 2017.
    • 17 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top